Drug · DIN 02550636
PAVBLU
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 3, 2025; first marketed September 3, 2025.
- Drug Identification Number (DIN)
- 02550636
- Company (DIN owner)
- Amgen Canada IncMississauga, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Intravitreal
- Therapeutic class (ATC)
- Aflibercept S01LA05
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| AFLIBERCEPT | 2 MG | 0.05 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 8, 2025: NOC 35672New Drug Submission (NDS)
Other DINs named PAVBLU
- DIN 02550628 · Approved